News

2014 Ovarian Cancer Statistics

(January 22, 2014) Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer... 

OCRF Research Identifies Biomarker that May Predict Treatment Response

Analisa DiFeo, PhD (January 13, 2014) Researchers at Case Western Reserve University, led by OCRF grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve... 

Meet OCRF’s 2014 Grant Recipients

OCRF is pleased to kick off our 20th anniversary with $6.5 million in research grants awarded to 22 scientists at leading medical institutions across the country. The 22 research grants awarded to 17 institutions include 12 new Ann Schreiber Mentored Investigator Awards to bright young ovarian cancer... 

OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option

OCRF Grantee Kunle Odunsi, MD, PhD New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy”... 

New Guidelines on Risk, Genetic Counseling & Testing for BRCA-related Cancer

(December 30, 2013)   The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of... 

High Volume Hospitals and Providers Improve Survival

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian... 

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp,... 

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers. ... 

Then & Now: 20 Years and Still Going Strong

OCRF Board Member, Robin Zarel, Celebrates 20 Years as an Ovarian Cancer Survivor Then – December 9, 1993 December 9, 1993 is a day that I will never forget. That was the day I had a radical hysterectomy for what was later found to be Stage III ovarian cancer.That was the bad news. The good is that... 

OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer

New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer.  The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial...